National Technology & Engineering Solutions of Sandia, LLC

Maxwell Stefan

Yooli Kim Light

Brooke Nicole Harmon

Jennifer Lauren Schwedler

Catherine Margaret Mageeney

Le Thanh Mai Pham

Christine Elizabeth Thatcher

Christopher Sumner

Disclosed herein are single-domain antibodies (sdABs) configured for targeting to human or mammalian lung tissue. Constructs and methods of using such sdABs are also described herein, such as methods of binding with and transporting other sdABs or other cargo with beneficial functionalities, binding to and transporting biochemical or pharmaceutical species with beneficial functionalities, and a method of treating, diagnosing, or prophylactically treating a disease, condition, or malignancy. A purification method for in vivo treatment or testing is also provided.

Lung-targeting single-domain antibodies and purification methods

Provided herein are single domain antibodies (sdAbs) configured for passing the blood brain barrier in a human or mammal brain. Methods of using such sdAbs are also described herein, such as methods of binding to brain cells, binding with and transporting other sdAbs with beneficial functionalities, binding to and transporting biochemical or pharmaceutical species with beneficial functionalities, and treating, diagnosing, or prophylactically treating a disease, malignancy, or condition.

Brain-targeting single domain antibodies and purification methods

Provided herein are asymmetric biparatopic neutralizing nanobody-based antibodies which engage SARS-2 spike in at least two independent epitopes. Several biparatopic constructs showed synergy in neutralizing viral infection of cells. Data also showed that single biparatopic constructs are more effective than the combination of the parental monotopic constructs were at neutralization. The nanobodies that were identified in an initial screen of a large and highly diverse library bind to a single epitope that overlaps with the ACE2 binding site.

Multivalent anti-SARS-CoV-2 nanobodies

The present disclosure relates to an isolated or purified antibody, or a fragment thereof, having a binding domain that binds to a coronavirus (e.g., SARS-COV-2) or a portion thereof. In other embodiments, the antibody includes a binding domain that competes with binding to angiotensin converting enzyme 2 (ACE2) or a portion thereof. Methods of using such antibodies are also described herein, such as methods of treating or delaying the progression of a disease associated with a coronavirus.

Growing community of inventors

Pleasanton, CA, United States of America

Maxwell Stefan